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Abstract
Background: The association of glycated albumin (GA) with mortality is unclear in chronic hemodialysis patients
with diabetes. We investigated the usefulness of GA by comparing it with hemoglobin A1c (HbA1c) in this patient
population.
Research design and methods: This was a multi-center, prospective cohort study of 841 Japanese chronic
hemodialysis patients with diabetes. There were 235 women and 606 men included, with a mean age of 64 years. The
primary and secondary endpoints were the incidence of all-cause and cause-specific mortality, respectively. The hazard
ratios of GA and HbA1c for the endpoints were estimated using the values at baseline and during the study period.
Results: During the mean follow-up period of 3.1 years, there were 184 deceased cases, in which 30 and 154 resulted
from atherosclerotic cardiovascular disease (ASCVD) and non-ASCVD, respectively. The hazard ratio for a 1% increase in
GA was 1.033 (95% confidence interval 1.006–1.060, p = 0.017) for all-cause mortality with a statistical significance when
GA was treated as a time dependent variable, but not when the baseline levels or the mean levels during the follow-
up period were used in the analysis (p = 0.815 and 0.517, respectively). GA was a significant predictor for ASCVD-related
mortality in the above 3 models, but was not for non-ASCVD mortality. Higher levels of HbA1c were only associated
with ASCVD-related mortality when HbA1c was treated as a time-dependent variable.
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Conclusions: GA may be useful compared to HbA1c for predicting all-cause and ASCVD-related mortality in Japanese
patients with diabetes undergoing chronic hemodialysis.
Background
The importance of glycemic control for preventing the de-
velopment and progression of microvascular complications
in patients with diabetes has been well established through
substantial randomized controlled trials [1]; nonetheless,
the role in these patients undergoing chronic dialysis re-
mains unclear, due to a lack of the randomized controlled
trials in this patient population. Previous cohort studies
have reported that higher levels of hemoglobin A1c
(HbA1c), the gold standard indicators of glycemic control,
predicted all-cause and cardiovascular mortality in patients
with diabetes undergoing chronic hemodialysis [2–4]. How-
ever, in patients with advanced stage of diabetic kidney dis-
ease (DKD), HbA1c values are underestimated due to
unpredictable changes in the survival time of erythrocyte,
leading to the unreliability of the HbA1c values [5, 6].
Glycated albumin (GA), reflecting average glucose levels
during the preceding 2 to 3 weeks, has been shown to be
preferable to HbA1c for the assessment of glycemic con-
trol in chronic hemodialysis patients with diabetes because
GA levels are not affected by the life span of erythrocytes
[5–7]. To date, few large cohort studies have reported an
association between GA and mortality in such patient
population [8, 9]; moreover, these studies were retrospect-
ively designed and did not evaluate GA values during the
study period, although these levels can vary over time.
Here, we prospectively investigated the usefulness of GA,
assessed based on both baseline and follow-up values, with
respect to mortality by comparing it with HbA1c in Japa-
nese chronic hemodialysis patients with diabetes.
Materials and methods
Study design and participants
This multi-center, prospective cohort study (UMIN clin-
ical trial registry number: UMIN000009036) was designed
in adherence to the Declaration of Helsinki, and was ap-
proved by the Ethics Committee of Tokyo Women’s Med-
ical University School of Medicine. All patients provided
written informed consent. A total of 972 adult patients
with diabetes receiving chronic hemodialysis at 39 Japa-
nese medical institutions were recruited between April
2013 and August 2015 for the present study. At baseline,
patients with a dialysis vintage less than 6 months or un-
known (n = 40) were excluded. This was because previous
large cohort studies of chronic hemodialysis patients have
shown that the effects of glycemic control on mortality
with short dialysis vintage, especially of less than 6
months, were noticeably different from those with the
longer vintage [4, 10]. Patients who had malignant disease
(n = 22), acute severe infection (n = 16), or who had miss-
ing baseline profile values (n = 6) were excluded. Patients
with liver cirrhosis (n = 7) or dysthyroidism (n = 40) were
also excluded because these conditions may impact GA
[11, 12]. Overall, data obtained from 841 participants were
analyzed in the present study (Supplementary Figure 1).
Measurements
Laboratory data were collected before each dialysis session
in 808 patients. For the remaining 33 patients, random spot
blood samples were taken when they visited Tokyo
Women’s Medical University School of Medicine for the
purpose of glycemic control. The samples were analyzed at
a central laboratory. GA, HbA1c, and glucose levels, most
of them were sampled postprandially, were determined by
an enzymatic method using the following: Lucica GA-L,
Asahi Kasei Pharma Co., Ltd., Tokyo, Japan; MetaboLead
HbA1c, Kyowa Medex Co., Ltd., Tokyo, Japan; and IatroLQ
GLU, Unitika Co., Ltd., Osaka, Japan; respectively. GA,
HbA1c, and glucose levels were measured at baseline and
every 6 months thereafter during the follow-up period.
Other laboratory data were measured at baseline. Informa-
tion on dialysis vintage, type of diabetes, medication, ath-
erosclerotic cardiovascular disease (ASCVD), smoking
status, body mass index (BMI), and blood pressure at base-
line were obtained from medical records at each institution.
Endpoints and follow-up
The primary and secondary endpoints were the incidence
of all-cause and cause-specific mortality, respectively, the
latter of which was classified into ASCVD-related and
non-ASCVD-related mortality. Ischemic heart diseases in-
cluding acute myocardial infarction, cerebral hemorrhage,
and cerebral infarction were defined as causes of ASCVD-
related death. Patients were censored when they under-
went kidney transplantation, transferred to a different
medical institution, lost to follow-up, or at the administra-
tive censoring date (December 31, 2017).
Statistical analysis
All analyses were completed using the SAS version 9.4
(SAS Institute Inc., Cary, NC, USA). Continuous data
were expressed as the arithmetic mean ± standard devi-
ation (SD), or median (interquartile range, IQR), as ap-
propriate. Categorical data were expressed as number
(%). A linear correlation between 2 variables was
assessed using the Pearson correlation coefficient. A
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cumulative incidence of the endpoints was estimated
using the Kaplan-Meier method. The multivariate Cox
proportional hazards models were used to estimate haz-
ard ratios and 95% confidence intervals (CIs). Possible
nonlinear associations were examined using the
multivariable-adjusted restricted cubic spline model [13],
with the 3 knots placed at the 10th, 50th, and 90th per-
centile levels. A comparison regarding the predictability
of GA and HbA1c levels for time to the endpoints was
assessed using the Uno’s overall C-statistics [14]. Three
sets of models were used to calculate the hazard ratios
(and 95% CI) of GA and HbA1c levels for the endpoints:
model 1, in which the hazard ratios were estimated using
baseline GA or HbA1c values; model 2, which used
mean values of GA or HbA1c during the follow-up
period; and model 3, in which GA or HbA1c values dur-
ing the follow-up period were treated as time-dependent
variables. All hazard ratios were adjusted by the follow-
ing variables: age, sex, dialysis vintage, type of diabetes,
use of angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers, history of ASCVD,
BMI, systolic blood pressure, hemoglobin, serum albu-
min, corrected calcium, phosphate, and non-high-
density lipoprotein cholesterol. Original clinical factors
used for the calculation of the overall C-statistics con-
sisted of the above 13 variables. Variation inflation fac-
tors (VIF) were calculated to check the multicollinearity
of the 13 variables; the values greater than 10 indicate
severe multicollinearity [15], and all VIFs among the 13
variables were less than 2. The measurements of GA and
HbA1c in 118 patients were partly missed after the study
began. The imputation of the missing data was not con-
ducted and only available data during the periods were
used in the analyses. A two-tailed p value less than 0.05
was considered significant.
We conducted several sensitivity analyses as follows.
First, we tested whether there are differences in the ef-
fects of GA levels on the endpoints depending on the
serum levels of albumin. Second, we used the Fine and
Gray subdistribution hazards model, considering the
presence of competing risks [16, 17]. In the present
study, non-ASCVD-related death was treated as a com-
peting risk in the analysis examining time to ASCVD-
related death, and vice versa. Third, we made a model
added diabetes therapy as covariates. Finally, we ana-
lyzed a model added levels of logarithmically trans-
formed high-sensitivity C-reactive protein, closely
associated with mortality in dialysis patients [18].
Results
Baseline characteristics
Of the 841 patients studied, there were 235 women and
606 men, with a mean (± SD) age of 64 ± 12 years. Me-
dian (IQR) dialysis vintage was 4.5 years (2.4–7.9 years).
Mean values of GA and HbA1c at baseline were 21.4 ±
5.0% and 6.4 ± 1.1%, respectively. There was a positive
and significant association between GA and HbA1c (r =
0.705, p < 0.001). Glucose levels also had a significant
positive association with GA (r = 0.419, p < 0.001) and
HbA1c levels (r = 0.390, p < 0.001), respectively. Other
clinical characteristics and laboratory data are presented
in Table 1.
Association of GA and HbA1c with mortality
During the mean (± SD) follow-up period of 3.1 ± 1.3
years, there were 184 deceased cases, in which 30 and
154 resulted from ASCVD and non-ASCVD, respectively
(Fig. 1). The details of death from ASCVD were ischemic
heart diseases in 12 patients and stroke in the other 18
patients. These from non-ASCVD were heart failure in
44 patients, infection in 23 patients, cancer in 16 pa-
tients, other causes in 30 patients, and unknown causes
in the other 41 patients. Five patients underwent kidney
transplantation, 143 were transferred to another institu-
tion, and 17 were lost to follow-up. As shown in Table
2, the hazard ratio for a 1% increase in GA was 1.033
(95% CI 1.006–1.060, p = 0.017) for all-cause mortality,
with a statistical significance in the analysis treating GA
as a time dependent variables (model 3). GA was a sig-
nificant predictor for ASCVD-related mortality in all 3
models, but was not for non-ASCVD-related mortality.
Higher levels of HbA1c were only associated with
ASCVD-related mortality in model 3; meanwhile, the
lower levels had a significant association with non-
ASCVD-related mortality in the analysis using baseline
HbA1c levels (model 1).
Next, we verified whether there is nonlinearity in the
associations of GA and HbA1c with the time to reach
the endpoints. The nonlinear association was rejected in
all analyses using baseline GA and HbA1c values (Fig.
2). In the analyses using the mean values during the
follow-up period, the results were not changed (Supple-
mentary Figure 2).
Finally, we compared the predictability of GA and
HbA1c for each endpoint (Table 3). When adding GA
or HbA1c values to the 13 original clinical factors, there
was no significant improvement in the overall C-
statistics in any analysis. The C-statistics of original fac-
tors plus GA were not significantly different from those
adding HbA1c in any analysis (Table 3).
Sensitivity analyses
There was no interaction between albumin and GA
levels with respect to the endpoints in any analysis (Sup-
plementary Tables 1). When patients were classified into
2 groups by the median of serum albumin levels (3.6 g/
dL), similar results to the above were obtained (Supple-
mentary Tables 1). In the Fine and Gray subdistribution
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hazards models, similar findings to the above were ob-
tained (Supplementary Tables 2). In models added dia-
betes therapy or levels of logarithmically transformed
high-sensitivity C-reactive protein, similar results were
obtained (Supplementary Tables 3 and 4).
Discussion
In this prospective cohort study, we have shown the use-
fulness of GA, assessed based on both baseline and
follow-up values, for predicting all-cause and ASCVD-
related mortality in chronic hemodialysis patients with
diabetes. The robustness of this finding was strength-
ened by conducting sensitivity analyses. Meanwhile,
higher levels of HbA1c were only associated with
ASCVD-related mortality when treated as a time-
dependent variable, suggesting that GA is a preferable
predictor for mortality compared to HbA1c in chronic
hemodialysis patients with diabetes.
In the present study, GA levels at baseline were not as-
sociated with all-cause mortality, unlike those assessed
as time-dependent variables, which was inconsistent
with previous reports [8, 9, 19, 20]. It is considered that
the Cox regression model with time-dependent variables
estimates the short-time effects of exposures, while that
with baseline variables estimates the long-time effects
[21, 22]. Therefore, the present findings may suggest
that short-term glycemic control has effects on mortality
in chronic hemodialysis patients with diabetes, consist-
ent with the present results showing no association of
mean GA values during the follow-up period with all-
cause mortality. A large retrospective cohort study in a
similar patient population from Japan showed a signifi-
cant association between increased GA levels at baseline
and all-cause mortality over a short follow-up duration
of 1 year [9], although the difference from the present
findings may simply be explained by the sample size.
Another retrospective study with the longer follow-up
periods of 4 years using the German Diabetes and Dialy-
sis Study cohort showed that higher levels of GA at
baseline were a significant predictor for all-cause mortal-
ity [8]. However, the incidence of cardiovascular mortal-
ity in chronic hemodialysis patients in Western
countries is obviously higher than that in Japan [23–25].
In the present study, higher levels of GA were associated
with ASCVD-related mortality in all models; therefore,
the difference in the incidence of cardiovascular disease
as the cause of death might explain the inconsistency be-
tween the German Diabetes and Dialysis Study and
present study.
Table 1 Baseline demographic and laboratory data
Overall (n = 841)
Age 64 ± 11 years
Men 606 (72.1%)
Dialysis vintage 4.5 years (2.4–7.9)
Type 1 diabetes 75 (8.9%)
Diabetes therapy
Insulin 344 (40.9%)
Other medication 369 (43.9%)
ACE inhibitors or ARBs 552 (65.6%)
Other antihypertensive drugs 600 (71.3%)
Statins 272 (32.3%)
History of ASCVD 333 (39.6%)
Current smoker 168 (20.0%)
Body mass index 23.5 ± 4.0 kg/m2
SBP 154 ± 23 mmHg
DBP 78 ± 13 mmHg
Laboratory data
GA 21.4 ± 5.0%
HbA1c 6.4 ± 1.1%
Glucose 145 ± 55 mg/dL
Hemoglobin 10.8 ± 1.1 g/dL
Albumin 3.6 ± 0.3 g/dL
Urea nitrogen 59.3 ± 15.2 mg/dL
Creatinine 10.5 ± 2.6 mg/dL
Potassium 4.9 ± 0.7 mEq/L
Corrected calcium 9.5 ± 0.7 mg/dL
Phosphate 5.6 ± 1.4 mg/dL
HDL cholesterol 45 ± 15 mg/dL
Non-HDL cholesterol 109 ± 32 mg/dL
Data are expressed as mean (standard deviation), median (interquartile range),
or number (percentage)
ACE angiotensin-converting enzyme, ARBs angiotensin receptor blockers,
ASCVD atherosclerotic cardiovascular disease, SBP systolic blood pressure, DBP
diastolic blood pressure, GA glycated albumin, HbA1c hemoglobin A1c, HDL
high-density lipoprotein
Fig. 1 Cumulative incidences of the endpoints with the number of
subjects at risk
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Unlike previous studies [4, 9], the present study did
not find a nonlinear association of GA and HbA1c
with the study endpoints. This inconsistency may be
due to a difference in the sample size. Indeed, the
above study from Japan showed a linear mortality
trend for GA; however, a sub-analysis using a larger
cohort found that very low levels of GA (< 12.5%)
were significantly associated with increased mortality
[9]. In the present study, the higher levels of HbA1c
in the analysis treating HbA1c as a time dependent
variables were associated with ASCVD-related mortal-
ity; meanwhile, the lower levels at baseline were a
predictor for non-ASCVD-related mortality, consistent
with previous large cohort studies showing a U-
shaped association between HbA1c values and all-
cause mortality [4, 9].
Table 2 Hazard ratio of 1% increase in GA and HbA1c levels for each endpoint
GA HbA1c
Cause of death Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
All-causes Model 1 1.00 (0.97–1.03) 0.815 0.87 (0.74–1.02) 0.088
Model 2 1.01 (0.98–1.05) 0.517 0.92 (0.77–1.11) 0.392
Model 3 1.03 (1.01–1.06) 0.017 1.01 (0.87–1.17) 0.888
Model 1 1.08 (1.01–1.15) 0.016 1.12 (0.80–1.58) 0.518
ASCVD Model 2 1.09 (1.02–1.17) 0.013 1.14 (0.78–1.66) 0.501
Model 3 1.10 (1.05–1.16) < 0.001 1.35 (1.02–1.77) 0.033
Model 1 0.99 (0.95–1.02) 0.477 0.82 (0.68–0.99) 0.034
Non-ASCVD Model 2 0.99 (0.96–1.03) 0.686 0.88 (0.71–1.08) 0.206
Model 3 1.01 (0.98–1.05) 0.409 0.93 (0.78–1.10) 0.374
Model 1, in which the hazard ratios were estimated using baseline GA or HbA1c values; model 2, which used mean values of GA or HbA1c during the follow-up
period; and model 3, in which GA or HbA1c values during the follow-up period were treated as time-dependent variables
ASCVD atherosclerotic cardiovascular disease, GA glycated albumin, HbA1c hemoglobin A1c
Fig. 2 Multivariable-adjusted restricted cubic spline curves (95% CI) of the association between baseline GA (a–c) or HbA1c levels (d–f) and each
endpoint, and the histogram of GA and HbA1c levels. Reference: median of GA (20.5%) or HbA1c (6.2%)
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The addition of GA or HbA1c values to existing risk
factors for mortality did not significantly improve pre-
dictability in the present study. Interestingly, a large co-
hort study of Canadian patients with diabetes reported
that the increased risk of end-stage kidney disease asso-
ciated with poor glycemic control was attenuated with
lower kidney function [26], in spite of glycemic control
being established as a major prognostic and interven-
tional factor for early stage of DKD [1]. In light of these
previous findings, together with the present study, gly-
cemic control in patient with advanced stage of DKD
has the modest or little impact on kidney function or
mortality.
The present study had several limitations. First, study
participants were from an ethnically homogenous popu-
lation in Japan. Therefore, the generalizability of the
present findings may be limited. Second, we were unable
to clarify the causal relationship between GA or HbA1c
and the endpoints because of the study design. Third,
we did not evaluate time-dependent changes in blood
pressure, BMI, medication, or laboratory data other than
indicators of glycemic control. Further, we did not ob-
tain information regarding the use of erythropoiesis-
stimulating agents. Fourth, we were also unable to con-
duct the analyses using the spline model and overall C-
statistics considering time-dependent effects of GA and
HbA1c values. Fifth, we did not conduct methods en-
couraging to account for bias due to missing data such
as multiple imputation and invers probability weighting.
Finally, a considerable number of patients were trans-
ferred to a different medical institution or lost to follow-
up, possibly biasing the present findings.
Conclusions
This multi-center, prospective cohort study provides evi-
dence that GA may be useful compared to HbA1c for
predicting all-cause and ASCVD-related mortality in
Japanese chronic hemodialysis patients with diabetes.
The importance of glycemic managements in this patient
population should be confirmed in future randomized
controlled trials targeting GA as indicators of glycemic
control.
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